Valrubicin

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

Host-guest complexes of cucurbituril with the neutral guest valrubicin: an experimental and computational study.

Host-guest complexes of cucurbituril with the neutral guest valrubicin: an experimental and computational study.

Journal: Drug development and industrial pharmacy

Published: November 25, 2025

A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.

A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.

Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica

Published: October 20, 2025

Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.

Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.

Journal: European urology focus

Published: March 11, 2025

Necrotizing Sialometaplasia of Tubarial Glands With Rouvière Lymphadenitis Complicating Postradiotherapy Tumor Follow Up.

Necrotizing Sialometaplasia of Tubarial Glands With Rouvière Lymphadenitis Complicating Postradiotherapy Tumor Follow Up.

Journal: The Laryngoscope

Published: February 16, 2025

Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review.

Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review.

Journal: Clinical genitourinary cancer

Published: December 20, 2024

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors.

NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: December 08, 2024

Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors.

Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: November 29, 2024

Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.

Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.

Journal: Research and reports in urology

Published: August 31, 2024

Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.

Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.

Journal: Anticancer research

Published: August 03, 2024

Identification of novel anti-leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach.

Identification of novel anti-leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach.

Journal: FEBS letters

Published: July 09, 2024

Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database.

Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database.

Journal: Expert opinion on drug safety

Published: July 01, 2024

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications.

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications.

Journal: Cancer letters

Published: June 04, 2024

Showing 1-12 of 98

Last Updated: 02/24/2026